WDTN Dayton news: FDA approves first melanoma cellular therapy
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, spoke with WDTN Dayton to discuss the approval of Amtagvi, the first cellular therapy for metastatic or unresectable melanoma, a harmful skin cancer.
“It’s actually a cellular therapy but its very different than the cellular therapies that are currently available for a lot of the hematologic malignancies,” said Wise-Draper, a University of Cincinnati Cancer Center member, section head of Medical Oncology and professor in the Division of Hematology/Oncology in UC’s College of Medicine.
The new therapy is for patients who have exhausted all other options.
“Because of the complicated nature of it, not everyone should get the therapy,” Wise-Draper said. “But for those that are fit and able to undergo the multiple treatments, cause it does require a very large multidisciplinary team.”
Wise-Draper said the Cancer Center's team of multidisciplinary experts will evaluate each patient to see if they are a fit for Amtagvi, since it is extensive.
“It’s really important that we evaluate the patient for feasibility upfront,” she said, “and make sure that’s something they’ll be able to undergo.”
Featured photo at top of Wise-Draper, left, and Vinita Takiar in their research laboratory. Photo/Colleen Kelley/UC Marketing + Brand
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.